AUTHORS
Christoph Schaefers, MD, Melinda Tan, MD2, Morie Gertz3, Taxiarchis Kourelis, MD4, Rahma Warsame, MD5, Joselle M Cook, M.D.6, Moritz Binder, MD, MPH7, Wilson Gonsalves, MD8, Chen Wu9, Angelo Jose Guilatco10, Andre De Menezes Silva Corraes, MD11, Malvika Gupta, MD12, Zuoyi Shao13, Kevin Regan14, Rayaan Kamal15, Amylou C Dueck, PhD16, Megan Weivoda, PhD17, Nadine Abdallah I, MD18, Yi Lin Jr, MD, PhD19
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Rochester, United States
ABSTRACT
Ciltacabtagene autoleucel (cilta-cel) produces high and durable response rates in relapsed/refractory multiple myeloma (RRMM), but most patients relapse. Therapy induced senescent-like (TIS) myeloma cells and T-cell phenotypes have been implicated in limited CAR T-cell expansion, persistence, and durability of response. Dasatinib and quercetin (D+Q) are senolytic drugs that can resensitize TIS MM cells to killing in preclinical models. We hypothesized that D+Q could improve the durability of CAR T-cell responses, without compromising the established safety profile of cilta-cel.
DART (NCT06940297) is an investigator-initiated, single-center, single-arm phase II trial. Eligible patients had received ≥3 prior lines of therapy (pLOT), were triple-class exposed, and had FDA-approved cilta-cel available. Patients receive 100 mg D and 1000 mg Q on Days -7/-6 prior to cilta-cel and on Days 28/29, 58/59 and 88/89 after cilta-cel, in combination with cilta-cel. The primary endpoint is MRD-negativity at 3 months by bone marrow and PET/CT. Secondary endpoints include response, progression-free survival, and adverse events. Correlative research includes longitudinal analysis of TIS. Here, we report an update on the pre-specified safety run-in.
Six patients (median age 67 yrs, range 58-72; 3 male/3 female) were included, with median of 3 pLOT. All patients were standard-risk by R-ISS and ECOG 0-1. Two patients held D for adverse events. No protocol-defined dose limiting toxicities (DLTs) occurred. Grade ≥3 hematologic AEs assessed as possibly or probably related to study treatment occurred in 4/6 patients, including grade 4 events in 2/6; all were protocol-defined DLT exceptions or resolved before day 90. Immune effector cell-associated adverse events were consistent with the known profile of cilta-cel: CRS occurred in 5/6 patients (no grade ≥3). No ICANS was observed. Median peak absolute lymphocyte count after infusion was 2.85 x109/l (1.02-5.46). D+Q did not negatively impact CAR+ T cell expansion or persistence, as CAR T+ cell counts were comparable to non-D+Q historical controls at Day 14 and months 1, as well as CD4/CD8 ratio, which is predominately CD8.
To date, no immune-effector cell associated delayed neurotoxicity has been observed. Post lymphodepletion, all patients had grade ≥3 hematologic toxicity. Grade ≥3 non-hematologic toxicity occurred in 3/6 patients (3/6 Hypertension, 1/6 catheter related infection, 1/6 pneumonia). Primary endpoint, bone marrow MRD and PET/CT negativity rate at month 3, was 83.3% (BM MRDneg 6/6, PET/CTneg 5/6). At months 6, bone marrow was MRD negative for 5/5 evaluable patients; PET/CT negative 4/5. With a median follow-up of 9 months (range 6-10), all patients remain progression-free at data cutoff.
In preliminary correlative analysis, baseline studies prior to infusion showed a TIS (KLRG1?) and myeloid (CD14+/CD16+) signature on myeloma cells. TIS T cells (CD3? KLRG1?) were seen in the bone marrow (55-80%). TIS T cells did not change over time in bone marrow compartment.
For future comparison to D+Q treated patients, longitudinal bone marrow samples (Pre CAR-T, 30 day, and 90 day) from a non-D+Q cilta-cel comparator cohort (N=15) were stained for CD138 and yH2AX to assess plasma cell burden and DNA damage, as a proxy for senescence. Those will be compared to D+Q treated patients.
In this pre-specified safety run-in of the DART trial (n=6), D+Q with cilta-cel was feasible and showed a safety profile consistent with the reported cilta-cel profile, and no new signals were associated with D+Q. CAR T-cell expansion and persistence was within the range of a non-D+Q cilta-cel comparator cohort. With a median follow-up of 9 months, all patients responded to cilta-cel and remained progression free. Recently, 3 additional patients were enrolled after the safety-run-in cutoff. Updated clinical and correlative results, including TIS analysis of serial bone marrow biopsies, will be reported.
DISCLOSURES
Christoph Schaefers, MD: Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony); Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony)